Companies › TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BBO-10203 PI3Kα:RAS breaker | PIK3CA, KRAS, NRAS, HRAS | Phase 1 | Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung Cancer | Aug 2027 |
| BBO-11818 pan-KRAS inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer | Aug 2027 |
| BBO-8520 KRAS G12C ON and OFF inhibitor | KRAS | Phase 1 | Non-small Cell Lung Cancer | Apr 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06917079 | BBO-11818 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT06917079 | BBO-10203 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT06625775 | BBO-10203 | Phase 1 | Solid Tumor, Adult | Oncology | Nov 2028 |
| NCT06343402 | BBO-10203 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Apr 2031 |
| NCT06343402 | BBO-8520 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Apr 2031 |
Eli Lilly Revolution Medicines Adlai Nortye Biopharma Roche Novartis Quanta Therapeutics Guangzhou JOYO Pharma Shanghai YingLi Pharmaceutical Bristol-Myers Squibb Amgen
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.